NeuroBo Pharmaceuticals Stock Forum

$NeuroBo Pharmaceuticals (NRBO.US)$
NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals (Nasdaq: NRBO) announced positive top-line data from Part 1 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog agonist for obesity treatment. The single ascending dose (SAD) study revealed favorable safety, tolerability, and dose-linear pharmacoki...

$NeuroBo Pharmaceuticals (NRBO.US)$ Reuters· 1 min ago
NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the Sad Part 1 of Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

$NeuroBo Pharmaceuticals (NRBO.US)$ 27PT August 2025.. hmm.. some interesting investors here too

$NeuroBo Pharmaceuticals (NRBO.US)$ needs more research but i remember this.. very well.. float got so low it couldnt move properly, almost due again

$NeuroBo Pharmaceuticals (NRBO.US)$
NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has completed enrollment for Part 1 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog agonist for obesity treatment. The single ascending dose (SAD) study enrolled 45 participants across 5 cohorts. No significant issues were encountered, allowin...

$NeuroBo Pharmaceuticals (NRBO.US)$
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has entered a joint research agreement with Dong-A ST and ImmunoForge to develop a long-acting, once-monthly formulation of DA-1726 for obesity treatment. DA-1726 is a novel, dual oxyntomodulin analog agonist functioning as a GLP1...

$NeuroBo Pharmaceuticals (NRBO.US)$
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has signed an exclusive license agreement with MThera Pharma for NB-01, a potential treatment for painful diabetic neuropathy.
The agreement grants MThera rights to conduct research and clinical trials, including a possible Phase 3 trial in the US and South Korea. This move aligns with NeuroBo's strategy to out-license legacy as...

$NeuroBo Pharmaceuticals (NRBO.US)$
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has dosed the first patient in Part 2 of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist for obesity treatment. This MAD study, expected to enroll 36 participants, will investigate safety, tolerability, and pharmacokinetics, with top-line data anticipated...

$NeuroBo Pharmaceuticals (NRBO.US)$  Top-Line Data Readout From Single Ascending Dose Part 1 Expected in Q3 2024 & From Multiple Ascending Dose Part 2 in Q1 2025